Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials (Q27853120)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials	scientific article

Statements

scholarly article

1 reference

PubMed publication ID

13 November 2016

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials (English)

1 reference

PubMed publication ID

13 November 2016

0 references

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

16

0 references

object named as

Sergey Orlov

19

0 references

James Chih-Hsin Yang

object named as

James Chih-Hsin Yang

1

0 references

object named as

Sanjay Popat

5

0 references

Michael J. Boyer

object named as

Michael Boyer

21

0 references

object named as

Wu-Chou Su

22

0 references

object named as

Tony Mok

20

0 references

Lecia V Sequist

28

object named as

Lecia V Sequist

0 references

author name string

Yi-Long Wu

2

0 references

Martin Schuler

3

0 references

Martin Sebastian

4

0 references

Nobuyuki Yamamoto

6

0 references

Caicun Zhou

7

0 references

Cheng-Ping Hu

8

0 references

Kenneth O'Byrne

9

0 references

Jifeng Feng

10

0 references

Shun Lu

11

0 references

Yunchao Huang

12

0 references

Sarayut L Geater

13

0 references

Kye Young Lee

14

0 references

Chun-Ming Tsai

15

0 references

Vera Hirsh

17

0 references

Jaafar Bennouna

18

0 references

Ki Hyeong Lee

23

0 references

Terufumi Kato

24

0 references

Dan Massey

25

0 references

Mehdi Shahidi

26

0 references

Victoria Zazulina

27

0 references

publication date

February 2015

0 references

Lancet Oncology Commission

0 references

16

0 references

2

0 references

141-51

0 references

Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971173-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971173-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971173-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971173-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971173-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971173-8

7 January 2021

based on heuristic

inferred from DOI database lookup

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971173-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971173-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971173-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971173-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971173-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971173-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971173-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971173-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Median follow-up in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971173-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Screening for epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971173-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971173-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971173-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971173-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971173-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971173-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971173-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)71173-8

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27853120&oldid=1535232413"